Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcus Biosciences reports strong Q3 performance with promising trial results

Arcus Biosciences delivered strong financial performance and promising clinical trial results in Q3 2023.
The company faces financial challenges amidst high R&D expenses but maintains a solid cash position and operational strength.
Strategic opportunities exist in advancing differentiated therapies, navigating competitive landscapes, and exploring combination treatments.
Successfully addressing challenges and capitalizing on opportunities can drive growth and market success for Arcus Biosciences.

Arcus Biosciences excels in Q4, poised for oncology innovation

Arcus Biosciences reported strong financials, positive program results, and strategic partnerships, positioning the company for continued growth and innovation in oncology.
Operational changes reflect a proactive approach to portfolio optimization and trial advancement, demonstrating Arcus's commitment to maximizing program potential and patient impact.
Challenges in data interpretation, program comparisons, and trial planning require careful navigation, while upcoming opportunities in 2024 offer avenues for showcasing progress and driving future success.
With a focus on expanding patient cohorts, optimizing doses, and revealing trial designs, Arcus is poised to capitalize on opportunities, address challenges, and deliver value to stakeholders.

Arcus Biosciences reports robust Q1 results and advances promising pipeline

Arcus Biosciences showcased strong financials, positive study data, and strategic partnerships, positioning them well for future growth and innovation.
While facing challenges in managing expenses and differentiation strategies, the company is actively exploring opportunities in combination therapies and tumor targeting.
The emphasis on good data, strategic planning, and leveraging biological insights highlights Arcus Biosciences' commitment to advancing drug development efforts and improving patient outcomes.

Arcus Biosciences reports promising clinical results and solid financials

Arcus Biosciences demonstrated strong clinical progress with casdatifan and domvanalimab, supported by solid financial performance. While challenges in clinical trial execution and market competition exist, the company is well-positioned to capitalize on opportunities for growth through upcoming Phase 3 studies and data presentations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced several poster presentations at upcoming scientific conferences that support the ongoing investigation of its clinical and preclinical pipeline. “Scientific exchange fosters progress in research, and we value the opportunity to contribute to the advancement of can

Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Q4 Earnings and Revenues Surpass Estimates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across common cancers, including lung

Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate at the following upcoming investor conferences: SVB Leerink 11th Annual Global Healthcare Conference Date & Time: Wednesday, February 16th, 2022 at 1:20 p.m. PT Format: Fireside Chat Barclay's Global Healthcare Conference Date &

Arcus Biosciences to Participate in the Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022. “Our priorities for 2022 are clear and unambiguous—to flawlessly execute on the expansion of our global clinical programs which will include more than 10 randomized Phase 2 and 3 studies. We also

Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones

Arcus Biosciences has compelling science but not much clinical data. Gilead has taken a very strong interest in the company.

Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add

Gilead Sciences

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gilead's option exercises to three programs in Arcus's clinical-stage portfolio and a new research collaboration between the two companies. On November 17, 2021, Gilead exercised its options to anti-TIGIT molecules domvanalimab and AB308, as well as clinical candidates etrumadenant (dual adenosine A2a/A2b receptor antagonist) and qu

Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration

Arcus was one of the few winners in the turbulent biotech space last month.

Why Arcus Biosciences Stock Vaulted Higher in November

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, and Taiho Pharmaceutical Co., Ltd., (“Taiho”), an R&D driven specialty pharma company with a focus on oncology, today announced that Taiho exercised its option for anti-TIGIT antibodies domvanalimab (development code: AB154) and AB308 from Arcus Biosciences (“Arcus”), in Japa

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences' Anti-TIGIT Program in Japan and Certain Territories in Asia

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx 2021 Conference. The fireside chat will take place on Wednesday, December 1st, 2021 at 4:20 p.m. ET. A live audio webcast of the fireside chat will be available by visiting the

Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference

BioMarin Pharmaceutical

BioNTech SE

Longeveron

Could these biotech stocks be poised for long-term gains?

4 Biotech Stocks To Watch This Week

Gilead Sciences Inc (NASDAQ: GILD) has exercised its options to three programs in Arcus Biosciences Inc (NYSE: RCUS) portfolio, including both anti-TIGIT molecules, domvanalimab, and AB308, as well as etrumadenant and quemliclustat. Under the terms Agreement, Arcus will receive option payments totaling $725 million for the three options that Gilead is exercising today.

Why Are Arcus Biosciences Shares Trading Higher Today?

Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.

Why Arcus Biosciences Stock Is On Fire Today

The stock price of Arcus Biosciences Inc (NYSE: RCUS) increased by over 10% pre-market today. This is why it happened.

Arcus Biosciences (RCUS) Stock: Why The Price Jumped Today

Shares of Arcus Biosciences Inc. RCUS, -1.10% rocketed 21% in premarket trading Thursday, after Gilead Sciences Inc. GILD, +0.85% said it's exercising options to three programs in the company's clinical-stage portfolio for payments of $725 million. The programs in question include anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat, treatments for different cancers.

Arcus Biosciences shares rocket premarket after Gilead exercises options for 3 cancer programs for $725 million

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced that Gilead has exercised its options to three programs in Arcus's clinical-stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat. The companies also added a research collaboration as described below. Today's transaction is subject to applicable antitrust clearance under the Hart-Sc

Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2021 and provided an update on the ARC-7 study of domvanalimab. Gilead Sciences has initiated its opt-in review process to potentially obtain rights to the Arcus anti-TIGIT program. If the option is exerci

Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for people with cancer, today announced that the company will report its financial results and a corporate update for the third quarter ended September 30, 2021 after the market closes on Monday, November 8, 2021. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical com

Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q3 Earnings Expected to Decline

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming September 2021 virtual investor conferences. Citi's 16th Annual Virtual Biopharma Conference, Friday, September 10 at 1:25 pm ET 2021 Cantor Virtual Global Healthcare Conference, Monday, September 27 at 4:40 pm ET A live audio webcast of the presentation will b

Arcus Biosciences to Participate at Upcoming Investor Conferences

Arcus Biosciences, Inc. (RCUS) CEO Terry Rosen on Q2 2021 Results - Earnings Call Transcript

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -41.56% and -48.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the second quarter ended June 30, 2021 and provided operational highlights. Management will host a conference call today, August 5, 2021 beginning at 1:30 pm PT/ 4:30 pm ET. “We have made significant progress advancing our portfolio and partnerships in the first half of 2021,” said Terry Rosen,

Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern Time. A live audio webcast of the presentation will be available by visiting the “Investors” section of the Arcus website at www.arcusbio.com. A replay of the webcast will be ava

News for Arcus Biosciences Stock (RCUS)